Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 31Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 19Neoplasm Metastasis 11Carcinoma, Hepatocellular 9Brain Neoplasms 8Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Lung Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Skin Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Mesothelioma 4Kidney Neoplasms 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Sarcoma 3Recurrence 3Myelodysplastic Syndromes 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Colorectal Neoplasms 3Breast Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 5Nivolumab 5selpercatinib 4Iodine-124 4Biopsy 4binimetinib 3Iodine-131 3Cetuximab 3ulixertinib 2trametinib 2pembrolizumab 2omipalisib 2larotrectinib 2defactinib 2dabrafenib 2Surveys and Questionnaires 2Sunitinib 2Radiosurgery 2Ipilimumab 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tipifarnib 1temsirolimus 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Ipilimumab × 90 days × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03914300 2026-06-01

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡